-
Product Insights
NewNet Present Value Model: Inhibrx Inc’s INBRX-101
Empower your strategies with our Net Present Value Model: Inhibrx Inc's INBRX-101 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence. emphysema. The therapeutic candidate comprises of alpha-1 antitrypsin (AAT)-Fc fusion proteins and developed...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dapagliflozin Propanediol in Diastolic Heart Failure (HFpEF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dapagliflozin Propanediol in Diastolic Heart Failure (HFpEF) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dapagliflozin Propanediol in Diastolic Heart Failure (HFpEF) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pritelivir Mesylate in Simplexvirus (HSV) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pritelivir Mesylate in Simplexvirus (HSV) Infections report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pritelivir Mesylate in Simplexvirus (HSV) Infections Drug Details: Pritelivir...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SPX-303 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SPX-303 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SPX-303 in Solid Tumor Drug Details: SPX-303 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TPIV-100 in Ductal Carcinoma In Situ
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TPIV-100 in Ductal Carcinoma In Situ report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TPIV-100 in Ductal Carcinoma In Situ Drug Details: TPIV-100...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sotatercept in Pulmonary Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sotatercept in Pulmonary Hypertension report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sotatercept in Pulmonary Hypertension Drug Details: Sotatercept (Winrevair) is an antihypertensive...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SNP-610 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SNP-610 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SNP-610 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: SNP-610...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anti-GPRC5D CAR T-cell Therapy in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anti-GPRC5D CAR T-cell Therapy in Relapsed Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anti-GPRC5D CAR T-cell Therapy in Relapsed Multiple...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anti-GPRC5D CAR T-cell Therapy in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anti-GPRC5D CAR T-cell Therapy in Refractory Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anti-GPRC5D CAR T-cell Therapy in Refractory Multiple...